| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 47,150 | 35,255 | ||
| Prepaid expenses | 33,432 | 120,822 | ||
| Total current assets | 80,582 | 156,077 | ||
| Marketable securities held in trust account | 179,899,077 | 178,025,297 | ||
| Total assets | 179,979,659 | 178,181,374 | ||
| Accounts payable and accrued expenses | 171,083 | 162,920 | ||
| Due to sponsor | 76,762 | 46,762 | ||
| Promissory note - related party | 100,000 | - | ||
| Accrued offering costs | 75,000 | 75,000 | ||
| Total current liabilities | 422,845 | 284,682 | ||
| Deferred underwriting fee | 6,037,500 | 6,037,500 | ||
| Total liabilities | 6,460,345 | 6,322,182 | ||
| Class a ordinary shares subject to possible redemption, 0.0001 par value 17,250,000 shares at redemption value of 10.43 and 10.11 per share as of september 30, 2025 and december 31, 2024, respectively-Classa Ordinary Shares Subject To Redemption | 179,899,077 | 178,025,297 | ||
| Common stock-Common Class B | 466 | 466 | ||
| Accumulated deficit | -6,380,229 | -6,166,571 | ||
| Total shareholders' deficit | -6,379,763 | -6,166,105 | ||
| Total liabilities, class a ordinary shares subject to possible redemption, and shareholders' deficit | 179,979,659 | 178,181,374 | ||
Translational Development Acquisition Corp. (TDACU)
Translational Development Acquisition Corp. (TDACU)